Qiming US Healthcare Fund led a $25 million Series B funding in ZappRx, a Boston company offering an automated specialty drug prescribing service. China's Qiming announced the $125 million US fund in January of this year. ZappRx said its platform is currently being used in several US academic medical centers and large multi-specialty practices. The specialty drug market, which involves ordering several products for combination regimens, is expected to reach $400 billion by 2020, according to ZappRx.
Source: ChinaBio Today
Please to leave a comment.